|Previous Section||Index||Home Page|
Dawn Primarolo: The Department funds national health service research and development through the National Institute for Health Research (NIHR). The Institute's health technology assessment programme is currently funding a project assessing deferasirox for the treatment of iron overload associated with regular blood transfusions in patients suffering with chronic anaemia; and the NIHR clinical research network is supporting a number of studies concerned with anaemia. Details of the latter can be found on the UK Clinical Research Network portfolio database at:
The Medical Research Council (MRC) is one of the main agencies through which the Government support medical and clinical research. The MRC is an independent body that receives its grant-in-aid from the Department for Innovation, Universities and Skills.
Mr. Greg Knight: To ask the Secretary of State for Health what recent estimate he has made of the proportion of invoices to his Department payable to small and medium-sized enterprises which are settled within 10 days. 
Mr. Bradshaw: The Department has configured its systems to enable its performance to be measured against 10-day targets announced by the Prime Minister on 8 October 2008. However, it is not possible at present to identify those suppliers that fall within the definition of small and medium sized enterprises.
The first formal data collection on performance against the 10-day target is being co-ordinated across Government by the Department for Business, Enterprise and Regulatory Reform based on November 2008 statistics. 98.02 per cent. of payments made to all suppliers, regardless of size, by the Department in November were made within 10 working days of receipt of the invoice.
Dr. Iddon: To ask the Secretary of State for Health (1) what recent discussions there have been between the National Institute for Health and Clinical Excellence and specialist clinicians on future appraisals of biosimilar medicines; and if he will make a statement; 
(2) what guidance his Department has issued to the National Institute for Health and Clinical Excellence (NICE) on the safety precautions to be reflected in NICE guidances on biosimilar medicines; and what account NICE takes of the safety precautions recommended by the Medicines and Healthcare Products Regulatory Agency and the European Medicines Agency in formulating such guidance. 
Phil Hope: The National Institute for Health and Clinical Excellence (NICE) is an independent body and should be approached directly for information on any recent discussions with specialist clinicians.
We have not issued any guidance to NICE on the appraisal of biosimilar medicines. Any relevant advice from the Medicines and Healthcare Products Regulatory Agency and the European Medicines Agency will be taken into account by NICE in its work.
Mr. Stephen O'Brien: To ask the Secretary of State for Health with reference to the answer of 4 November 2008, Official Report, columns 371-76W, on cancer: drugs, what the eligible patient population for each treatment was in each (a) month and (b) year; and how many of the eligible patient population died in each (i) month and (ii) year. 
Mr. Stephen O'Brien: To ask the Secretary of State for Health with reference to the answer of 19 November 2008, Official Report, column 518W, on the elderly: mentally incapacitated, which of the care homes were run by (a) private sector companies, (b) local authorities and (c) third sector organisations. 
Mr. Graham Stuart: To ask the Secretary of State for Health how many (a) care homes and (b) care home places for people suffering from dementia there were in each local authority area in Yorkshire and the Humber in each of the last 10 years; and if he will make a statement. 
Phil Hope: We are informed by the Commission for Social Care Inspection (CSCI) that it does not register care homes according to the number of people from a specific client group, such as those suffering dementia, which they may accommodate. CSCI will register a home as being able to care for at least one person from a particular client group. CSCI is able to produce data from 2004. Information from earlier years is not available centrally.
The following table shows the numbers of care homes and registered places in each local authority area within the Yorkshire and Humberside region where at least one place in the home is registered as at 15 December 2008 to provide dementia care.
|Number of care homes and registered places in Yorkshire and Humberside where at least one place in the home is registered to provide dementia care( 1)|
|Year ending 31 March||2004||2005||2006||2007||2008|
|(1) Homes are not registered according to the actual number of places they have for each client group. They indicate which groups they can provide at least one place for. The number of registered places shown is for all client groups homes have informed CSCI they can accommodate as at 15 December 2008. This is because CSCI does not hold historic data for client group registration.|
(2) Local council data are derived from the postcode of the service. Where post code is not provided the service is recorded as Unknown.
CSCI database (static cut 02/05/08).
|Next Section||Index||Home Page|